BioNTech (NASDAQ:BNTX) Price Target Raised to $136.00 at HSBC

BioNTech (NASDAQ:BNTX) had its target price boosted by HSBC from $97.00 to $136.00 in a research note issued to investors on Monday, Benzinga reports. HSBC currently has a buy rating on the stock.

A number of other research firms also recently issued reports on BNTX. UBS Group lifted their price objective on BioNTech from $97.00 to $131.00 and gave the stock a neutral rating in a research note on Wednesday, September 18th. Morgan Stanley raised shares of BioNTech from an equal weight rating to an overweight rating and upped their price target for the company from $93.00 to $145.00 in a research note on Tuesday, September 24th. Hsbc Global Res raised shares of BioNTech from a hold rating to a strong-buy rating in a research note on Friday, August 2nd. Jefferies Financial Group upgraded shares of BioNTech from a hold rating to a buy rating and boosted their target price for the stock from $96.00 to $150.00 in a report on Tuesday, September 17th. Finally, JPMorgan Chase & Co. raised shares of BioNTech from an underweight rating to a neutral rating and increased their price target for the company from $91.00 to $125.00 in a report on Monday, September 16th. Five investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of Moderate Buy and an average target price of $131.92.

BioNTech Trading Up 0.8 %

BNTX stock opened at $118.37 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.40. The business has a 50 day simple moving average of $100.13 and a two-hundred day simple moving average of $93.16. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49. The company has a market capitalization of $28.14 billion, a price-to-earnings ratio of 236.74 and a beta of 0.24.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The company had revenue of $128.70 million for the quarter, compared to the consensus estimate of $134.98 million. During the same period last year, the company earned ($0.86) EPS. The firm’s revenue for the quarter was down 23.3% on a year-over-year basis. Research analysts anticipate that BioNTech will post -2.87 EPS for the current fiscal year.

Institutional Trading of BioNTech

A number of large investors have recently made changes to their positions in the stock. GAMMA Investing LLC increased its stake in BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after buying an additional 111 shares during the period. Covestor Ltd raised its stake in shares of BioNTech by 47.2% during the first quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after acquiring an additional 133 shares in the last quarter. Midwest Professional Planners LTD. raised its stake in shares of BioNTech by 7.2% during the first quarter. Midwest Professional Planners LTD. now owns 3,177 shares of the company’s stock valued at $293,000 after acquiring an additional 212 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in shares of BioNTech by 2.3% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 9,800 shares of the company’s stock valued at $904,000 after purchasing an additional 223 shares during the period. Finally, EverSource Wealth Advisors LLC grew its stake in BioNTech by 106.3% in the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after purchasing an additional 252 shares in the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.